Phoenix PharmaLabs, Inc.
525 West 465 North
Suite 150
Providence
Utah
84332-5604
United States
Tel: 435-752-2412
Fax: 435-752-1996
Website: http://phoenixpharmalabs.com/
12 articles with Phoenix PharmaLabs, Inc.
-
Phoenix PharmaLabs Successfully Completes Second Oversubscribed Netcapital Offering Raising more than $1 million to Fund Continued Development of Company’s Two Non-Addictive Opioid Compounds for Acute and Chronic Pain
6/23/2021
Phoenix PharmaLabs, Inc. today announced it has completed a second successful round of financing raising $1.07 million via the Netcapital ( https://netcapital.com ) equity funding portal.
-
Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with the Acquisition of a Portfolio of NOP/Mu Agonist Compounds
1/5/2021
Phoenix PharmaLabs, a privately-held pre-clinical drug discovery company dedicated to the development of potent, non-addictive treatments for pain and addiction, today announced it has completed a license agreement with the University of Bath in England for exclusive rights to a portfolio of 25 NOP (Nociceptin) compounds. The specific terms of the license agreement were not disclosed. One of the compounds, formerly kn
-
Phoenix PharmaLabs Announces New Investment Offering with Netcapital
12/21/2020
Phoenix PharmaLabs, a privately held, preclinical drug company dedicated to developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform: https://netcapital.com/companies/phoenix .
-
Phoenix PharmaLabs Raises More Than $1.1 Million via Netcapital
4/8/2019
Funds to accelerate development of first non-addictive opioid
-
Phoenix PharmaLabs: How Would Physicians Spend One Billion Dollars to Combat Opioid Crisis?
3/5/2019
85% Surveyed Said First Priority Is to Fund Research into Non-Addictive Pain Killers
-
Phoenix PharmaLabs Announces Investment Offering to Support Additional Research of Non-Addictive Opioid
10/15/2018
Phoenix PharmaLabs today announced the launch of an equity offering campaign on the Netcapital platform.
-
Phoenix PharmaLabs Awarded $2.7 Million Research Grant from DOD/USAMRAA for Further Development of Non-Addictive Opioid
9/25/2018
Phoenix PharmaLabs has been awarded a $2.7 million grant from the Department of Defense/US Army Medical Research Acquisition Activity.
-
Phoenix PharmaLabs Awarded NIH/NIDA Grant to Study Non-Addictive Opioid PPL-103 for Potential use as Cocaine Addiction Therapy Drug
9/5/2018
This research is supported under award number R41DA044894.
-
Phoenix PharmaLabs Co-Founder to speak at Upcoming College on Problems of Drug Dependence (CPDD) 80th Annual Meeting in San Diego
5/24/2018
Lawrence Toll, Ph.D., expected to describe company’s novel opioid that shows no signs of addiction potential
-
Phoenix PharmaLabs, Inc. Releases New Data Confirming That Their Novel Opioid Shows No Signs Of Addiction Potential
1/6/2016
-
Novel Painkiller With Little Or No Signs Of Addiction And Other Serious Opioid Side Effects Patented By Phoenix PharmaLabs, Inc.
4/8/2015
-
Aoxing Pharmaceutical Company Inc. and Phoenix PharmaLabs, Inc. Announce Strategic Alliance to Co-Develop a Novel Class of Molecules in Pain and Drug Addiction Therapeutics
6/3/2010